Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxart Inc VXRT

Healthcare Biotechnology
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its... see more

Recent & Breaking News (NDAQ:VXRT)

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

GlobeNewswire February 3, 2021

VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire January 29, 2021

Glancy Prongay & Murray LLP Announces Investigation of Vaxart, Inc.

Business Wire January 27, 2021

Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine

GlobeNewswire January 27, 2021

Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication

GlobeNewswire January 26, 2021

Did You Acquire (VXRT) Before June 25, 2020? Johnson Fistel Investigates Vaxart; Should Management be Held Accountable for Investors Losses?

PR Newswire January 8, 2021

Vaxart Hosting Key Opinion Leader Panel Call for Investors

GlobeNewswire November 16, 2020

Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference

GlobeNewswire November 16, 2020

Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 12, 2020

Vaxart Announces Additional Data from Hamster Challenge Study of its Oral COVID-19 Vaccine

GlobeNewswire November 12, 2020

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile October 23, 2020

VXRT Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Vaxart, Inc. Investors With Losses Exceeding $500K of Class Action and Lead Plaintiff Deadline: October 23, 2020

Newsfile October 23, 2020

VXRT DEADLINE TODAY: Hagens Berman, National Trial Attorneys, Alerts Vaxart (VXRT) Investors of Today's Deadline to Move for Lead Plaintiff

ACCESSWIRE IA October 23, 2020

VXRT FINAL DEADLINE TODAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Reminds Vaxart, Inc. Investors of Important October 23 Deadline in Securities Class Action - VXRT

GlobeNewswire October 23, 2020

Vaxart, Inc. Investors: Portnoy Law Advises Last Days to Participate Actively in the Class Action Lawsuit

GlobeNewswire October 23, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Vaxart, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2020 - VXRT

Newsfile October 22, 2020

VXRT FINAL DEADLINE NOTICE: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Friday Deadline in Securities Class Action - VXRT

PR Newswire October 22, 2020

FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA October 22, 2020

VXRT Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Vaxart, Inc. Investors With Losses Exceeding $500K of Class Action and Lead Plaintiff Deadline: October 23, 2020

Business Wire October 22, 2020

FINAL DEADLINE FRIDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA October 22, 2020